Role of lenalidomide in the treatment of peripheral T-cell non-Hodgkin lymphomas

Table 1 Clinical results of approved novel agents as monotherapy for relapsed/refractory T-cell lymphomas

Ref.	Patients, n	Study design	Treatment	Mechanism of action	Histology,	ORR	CR rate	Median PFS	Median DOR	Median OS
					(number of patients)
O’Connor et al[10], 2011	111	Multicenter phase II	Pralatrexate	Antifolate	Total evaluable (109)	29%	11%	3.5 mo	10.1 mo	14.5 mo
					PTCL-NOS (59)
					ALCL (17)	32%	NA
					AITL (13)	35%	NA
					MF (12)	8%	NA
					Other (8)	25%	NA
						38%	NA
Coiffier et al[11], 2014	130	Multicenter phase II	Romidepsin	Histone deacetylase inhibitor	Total evaluable	25%	15%	4 mo	28 mo	11.3 mo
					-130
					PTCL-NOS (69)	29%	14%
					ALCL ALK- (21)	24%	19%
					AITL (27)	30%	19%
					Other (13)	/	/
O’Connor et al[12], 2015	129	Multicenter phase II	Belinostat	Histone deacetylase inhibitor	Total evaluable	25.80%	10.80%	1.6 mo	13.6 mo	7.9 mo
					-120
					PTCL-NOS (77)	23%	NA
					ALCL ALK- (13)	15%	NA
					ALCL ALK+ (2)	/	NA
					AITL (22)	46%	NA
					Other (6)	16.60%	NA
Pro et al[13], 2017	58	Multicenter phase II	Brentuximab vedotin	Monoclonal antibody anti-CD30	ALCL	86%	57%	20 mo	25.6 mo	NR (estimated 5-yr OS 60%)
Kim et al[14], 2018	186	Multicenter, randomized, phase III	Mogamulizumab	Monoclonal antibody anti C-C chemokine receptor 4	MF or Sézary syndrome	28%	2.70%	7.7 mo	14.1 mo	NR

AITL: Angioimmunoblastic T-cell lymphoma; ALCL: Anaplastic T-cell lymphoma; ALK: Anaplastic lymphoma kinase; CR: Complete response; DOR: Duration of response; MF: Mycosis fungoides; NA: Not available; NR: Not reached; ORR: Overall response rate; OS: Overall survival; PFS: Progression-free survival; PTCL-NOS: Peripheral T-cell lymphomas: not otherwise specified.